Zymeworks (ZYME)
Develops antibody medicines and earns royalties from partner-run therapies.
$27.27
vs last close+0.46 (+1.72%)
Something off on this page? Send us feedback.
Next report
Nov 5, 26
in 44 days
EPS estimate
$2.44
Revenue estimate
$233.7M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.31−$0.30$0.03−$0.26−$0.55−$0.59−$0.62Pending
Estimate$0.01−$0.45−$0.52−$0.30−$0.35−$0.10−$0.57$2.44
Surprise−3,200.0%+33.3%+105.8%+13.3%−57.1%−490.0%−7.9%—
RevenueReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$31.0M$27.1M$48.7M$27.6M$2.5M$2.4M$4.6MPending
Estimate$15.2M$18.0M$25.7M$19.5M$19.2M$24.4M$4.5M$233.7M
Surprise+104.2%+50.4%+89.3%+41.7%−86.9%−90.1%+1.2%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2027 | −$0.01 | — | — |
| Sep 2027 | $0.28 | — | — |
| Jun 2027 | −$0.06 | — | — |
| Mar 2027 | $0.29 | — | — |
| Dec 2026 | $0.21 | — | — |
| Nov 2026 | $2.44 | — | — |
| Aug 2026 | −$0.57 | −$0.62 | −7.9% |
| May 2026 | −$0.10 | −$0.59 | −490.0% |
| Mar 2026 | −$0.35 | −$0.55 | −57.1% |
| Nov 2025 | −$0.30 | −$0.26 | +13.3% |
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Oct 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Feb 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Feb 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Mar 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Mar 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Apr 2017 | |||
| Sep 2016 | |||
| Jun 2016 | |||
| Mar 2016 | |||
| Dec 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2027 | −$0.01 | — | — | $35.3M | — | — | — |
| Sep 2027 | $0.28 | — | — | $102.5M | — | — | — |
| Jun 2027 | −$0.06 | — | — | $66.4M | — | — | — |
| Mar 2027 | $0.29 | — | — | $92.8M | — | — | — |
| Dec 2026 | $0.21 | — | — | $73.6M | — | — | — |
| Nov 5, 2026 | $2.44 | — | — | $233.7M | — | — | — |
| Aug 6, 2026 | −$0.57 | −$0.62 | −7.9% | $4.5M | $4.6M | +1.2% | +1.8% |
| May 7, 2026 | −$0.10 | −$0.59 | −490.0% | $24.4M | $2.4M | −90.1% | −10.2% |
| Mar 2, 2026 | −$0.35 | −$0.55 | −57.1% | $19.2M | $2.5M | −86.9% | +0.1% |
| Nov 6, 2025 | −$0.30 | −$0.26 | +13.3% | $19.5M | $27.6M | +41.7% | −8.0% |
| Aug 7, 2025 | |||||||
| May 8, 2025 | |||||||
| Mar 5, 2025 | |||||||
| Oct 31, 2024 | |||||||
| Aug 1, 2024 | |||||||
| May 2, 2024 | |||||||
| Mar 6, 2024 | |||||||
| Nov 7, 2023 | |||||||
| Aug 10, 2023 | |||||||
| May 8, 2023 | |||||||
| Mar 7, 2023 | |||||||
| Nov 8, 2022 | |||||||
| Aug 4, 2022 | |||||||
| May 4, 2022 | |||||||
| Feb 24, 2022 | |||||||
| Nov 3, 2021 | |||||||
| Aug 4, 2021 | |||||||
| May 5, 2021 | |||||||
| Feb 24, 2021 | |||||||
| Nov 3, 2020 | |||||||
| Aug 5, 2020 | |||||||
| May 7, 2020 | |||||||
| Mar 2, 2020 | |||||||
| Nov 5, 2019 | |||||||
| Aug 2, 2019 | |||||||
| May 2, 2019 | |||||||
| Mar 6, 2019 | |||||||
| Nov 6, 2018 | |||||||
| Aug 1, 2018 | |||||||
| May 1, 2018 | |||||||
| Mar 14, 2018 | |||||||
| Nov 8, 2017 | |||||||
| Aug 8, 2017 | |||||||
| May 15, 2017 | |||||||
| Apr 28, 2017 | |||||||
| Sep 30, 2016 | |||||||
| Jun 30, 2016 | |||||||
| Mar 31, 2016 | |||||||
| Dec 31, 2015 |